Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Boehringer Ingelheim Animal Health, Veterinary Vaccine Manufacturing Plant in Taizhou, China

Boehringer Ingelheim began building a world-class veterinary vaccine manufacturing plant in Taizhou in 2013, thus demonstrating its commitment to being ’in China, for China’. The first phase of the plant, with a total investment of 85 million euros, was completed in 2016. The plant’s manufacturing facilities, production process, quality control system and staffing meet Good Manufacturing Practice (GMP) standards in the EU; in December 2017, the Taizhou plant obtained GMP certification from the Ministry of Agriculture of China. The annual production capacity of the Taizhou plant reaches 125 million doses, with Ingelvac® PRRS MLV as the first product made locally. *

 

Period Start 2019-01-24 existent
Products Industry animal vaccine
  Industry 2 Ingelvac® PRRS MLV swine vaccine
     
Region Region Taizhou, Jiangsu
  Country China
  City n. a. Taizhou, Jiangsu province
    Address record changed: 2019-02-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Boehringer Ingelheim. (1/24/19). "Press Release: Boehringer Ingelheim Launches First Veterinary Vaccines Produced in China". Ingelheim.
     
   
Record changed: 2023-07-10

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Boehringer Ingelheim Animal Health, Veterinary Vaccine Manufacturing Plant in Taizhou, China


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top